6 November 2025 - PHARMAC is proposing changes to the Special Authority and Hospital Indication Restrictions criteria for four biologic medicines: infliximab, etanercept, secukinumab, and rituximab.

These medicines are used to treat a range of auto-immune and inflammatory conditions. The proposed changes aim to reduce administrative workload for clinicians, improve consistency across biologic treatments, and respond to feedback received during previous consultation.

Read PHARMAC press release